Overview

Study Evaluating TTI-237 in Advanced Malignant Solid Tumors

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Criteria
Inclusion Criteria:

- Documented diagnosis of malignant solid tumor with measurable disease

- Life expectancy of at least 12 weeks

- ECOG performance status of 0, 1, or 2

Exclusion Criteria:

- Recent major surgery, radiation therapy or anti-cancer treatment

- History of any other prior malignancy within the last 5 years